We're sorry, but all tickets sales have ended because the event is expired.
  •  November 17, 2022
     1:00 pm - 2:00 pm


Cohn Reznick

ESG has become increasingly more important for all stakeholders in the life science industry. As such, organizations are taking inventory of the current state of ESG programs, and are developing new strategies and roadmaps to create safer products to enhance the patient experience and journey. Organizations are focusing on quality beyond compliance, enhancing reporting to promote improved transparency across the broad spectrum of stakeholders, and are strategizing on ways to engage underserved communities through clinical trial programs; all of which fold into the three pillars of ESG. Comprehension of the maturity of an organization’s ESG program is imperative to developing a robust future state roadmap and strategy to meet the needs of stakeholders.

A strong and well-documented ESG strategy and program is imperative to the future state of the life science industry as a whole. Please join members of CohnReznick’s ESG Global Consulting Services Advisory team for a live discussion to better understand the current state of ESG and hear our take on defining the future state of ESG in life sciences.